Acetyl-L-carnitine for dementia
BMC Psychiatry 23 (1), 806
International scheduling Australia's Therapeutic Goods Administration (interim decision, April 2024) and New Zealand's Medsafe (Medicines Classification Committee, June 2025) have moved to schedule BPC-157 as a prescription-only medicine, despite its unavailability through legitimate prescription
Its primary mechanism is angiogenesis: BPC-157 helps trigger new blood vessel growth in injured tissue, which is what allows it to support repair in tendons, ligaments, the gut lining, and joints
View available lab results Exclusively intended for research purposes
And when combined with semaglutide in the CagriSema combination , those GI numbers climbed even further, with 79.6% of participants experiencing some form of gastrointestinal event